Elsevier

Vaccine

Volume 15, Issue 14, October 1997, Pages 1506-1511
Vaccine

Paper
Influenza vaccination in 22 developed countries: an update to 1995

https://doi.org/10.1016/S0264-410X(97)00091-1Get rights and content

Abstract

This study expands and updates through 1995 our earlier report on influenza vaccine use in 18 developed countries. Five of the six countries with high levels of vaccine use in 1992 (≥130 doses/1000 population) showed little change or slight declines over the subsequent 3 years. The exception was the United States, where a new federal program for vaccination reimbursement for the elderly helped to increase vaccine distribution from 144 to 239 doses/1000 population. The six countries with medium levels of vaccine use in 1992 (76–96 doses/1000 population) increased to ≥100 doses/1000 population by 1995. Among the six low-use countries in 1992 (≤65 doses/1000 population), only Finland showed substantial improvement (96 doses/1000 population) in 1995. Four new countries were added to the study. In Germany, vaccine use increased to 80 doses/1000 population in 1995, but in Ireland it remained at a low level (48 doses/1000 population). In Korea, vaccine use increased from 17 to 95 doses/1000 population during the period 1987–1995. In Japan, very high levels of vaccine use (≈280 doses/1000 population) in the early 1980s were associated with vaccination programs for school children. However, vaccine use fell precipitously when these programs were discontinued, and only 2 and 8 doses/1000 population were used in 1994 and 1995, respectively. In all 22 countries, higher levels of vaccine use were associated with vaccination reimbursement programs under national or social health insurance and were not correlated with different levels of economic development. Excluding Japan, in 1995 there was still a greater than fourfold difference between the highest and lowest levels of vaccine use among the other 21 countries in the study. Given its well established clinical effectiveness and cost-effectiveness, none of these countries has yet achieved the full benefits of its programs for influenza vaccination.

References (19)

There are more references available in the full text version of this article.

Cited by (84)

  • Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China

    2021, Vaccine
    Citation Excerpt :

    Given that nearly 90% of the elderly in Shenzhen who received influenza vaccines also received PPSV23 and that very few people received either of the vaccines outside of the immunization program, we did not compare dual vaccination with either vaccine alone in this study to avoid substantial deviation from real-world practice. Subsidizing vaccination is important for the uptake of influenza and pneumococcal vaccines [43]. In some countries, especially those providing free influenza and pneumococcal vaccines, the vaccination rates are relatively high.

  • Seasonal influenza vaccination in China: Landscape of diverse regional reimbursement policy, and budget impact analysis

    2016, Vaccine
    Citation Excerpt :

    Thus, vaccine uptake in China falls substantially below the World Health Assembly (WHA) target of 75% in the elderly by 2010 [12], and also below that of other upper-middle income countries such as Brazil where coverage is over 70% in the elderly [6]. In countries where vaccination costs are subsidized by the respective governments, there is higher national vaccine uptake [13,14]. To our knowledge, only a handful of large cities in China currently provide reimbursement for influenza vaccination.

  • Influenza vaccination in Austria from 1982 to 2011: A country resistant to influenza prevention and control

    2013, Vaccine
    Citation Excerpt :

    In 1996, the European Scientific Working Group on Influenza (ESWI) took over the project. The work of these groups led to four publications [14–17], which have provided a foundation for understanding the macro-epidemiology of influenza vaccination throughout the world. Data from this source cover the years from 1980 to 2003 in three study periods: 1980–1992, 1992–1995, and 1996–2003.

  • Genetic characterization of circulating seasonal Influenza A viruses (2005-2009) revealed introduction of oseltamivir resistant H1N1 strains during 2009 in eastern India

    2010, Infection, Genetics and Evolution
    Citation Excerpt :

    The results reconfirms importance of Influenza surveillance is of utmost importance in the south-east and eastern Asian countries, since it is predicted that this region “seeds” the subsequent annual seasonal epidemics (Ahmad et al., 2000). As strains from Taiwan (Fedson et al., 1997) as well as Eastern India precede vaccine strains, contribution of strains from this region to the Global Influenza Surveillance Network (GISN) is important. However, plethora of information on HA and NA gene sequences from different locations of India as well as other Asian countries are required for significant contribution in GISN.

View all citing articles on Scopus
View full text